Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00563576 · ClinicalTrials.gov registry record · NA

Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation

A NA study of Metrorrhagia, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
71
Enrollment target
1
Study location

NCT00563576 is a NA study of Metrorrhagia that has completed, run by Columbia University. The registered enrollment target is 71 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00563576, a NA study of Metrorrhagia, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

Many women choose Depo-Provera for birth control because it is easy to use and very effective. However, a significant number of Depo-Provera users experience irregular bleeding during the first 90 days. Many users discontinue after their first injection due to irregular bleeding. This study will evaluate the effect of using an estrogen vaginal ring during the first 90 days of Depo-Provera use to see if it is acceptable to women and whether it decreases irregular bleeding during the first 90 days of use and increases continuation to a second injection.

Conditions Studied

Interventions

  • DRUG Femring®
  • DRUG DepoProvera ®

Study Locations (1)

New York

  • Title X Family Planning Clinic - New York

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2007-09
Est. Completion 2009-02
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT00563576

The ClinicalTrials.gov registry entry for NCT00563576 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metrorrhagia appearing as the primary indexed condition, and to 2 interventions - of which Femring® is the first listed.

NCT00563576 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00563576 about?

NCT00563576 is a clinical study titled "Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation". Many women choose Depo-Provera for birth control because it is easy to use and very effective. However, a significant number of Depo-Provera users experience irregular bleeding during the first 90 days. Many users discontinue after their first injection due to irregular bleeding. This study will eva...

What is the current status of trial NCT00563576?

This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2007-09. Estimated completion is 2009-02.

What conditions does trial NCT00563576 study?

This clinical trial studies the following conditions: Metrorrhagia.

What interventions are being tested in trial NCT00563576?

The interventions under investigation include: Femring® (DRUG), DepoProvera ® (DRUG).

Who is sponsoring clinical trial NCT00563576?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00563576 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metrorrhagia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.